ClinicalTrials.gg
Not yet recruitingNCT06401395AWAKENINGUpdated May 9, 2024

Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING)

An interventional study of DIGIPARK MONITOR in Parkinson Disease, sponsored by DIAMPARK. Not yet recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by DIAMPARK · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.

Planned enrollment
49th of 328
300 · median 64
Started
2024
with 14 others
No phase
179 of 428
36 open now
Primary completion
2027-01
later than 34 of 75 live
Registered
388th of 428
by date

Among the 428 studies in Parkinson Disease with a site in France, this one is the 49th largest by planned enrollment of the 328 interventional ones that give a count, is one of 15 that started in 2024, is one of 179 with no phase, reaches primary completion later than 34 of the 75 other live ones, and was the 388th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 428 studies in Parkinson Disease with a site in France, or all of them as a file.
02

Study summary

Parkinson's disease (PD) ranks second among neurodegenerative diseases and is a major cause of neurological motor disability. The number of PD cases doubled between 1990 and 2016. The consequences of PD, including an increased risk of falls, loss of autonomy and reduced quality of life, contribute to increased morbidity and mortality. The costs associated with falls in the elderly (a fortiori those with PD) and their consequences represent between 0.85% and 1.5% of total healthcare expenditure.

There is currently no cure for PD. Treatment is symptomatic and depends on the degree of functional impairment and the age of onset. After a period of stabilization (state phase) of varying length, the clinical situation worsens because of treatment-related motor complications (motor fluctuations, on/off phenomena, dyskinesias, under/overdosing) and the appearance or worsening of disease-specific signs linked to the pathogenic process. Treatment of motor complications involves constantly adjusting doses and dosing schedules to suit each individual case, and to take account of variations in the patient's motor status over the months. These adjustments must also take into account the non-motor signs of the disease, notably thymic fluctuations, treatment-related behavioral disorders, fatigue, sensory and pain disorders. Regular follow-up of patients is therefore essential to assess the evolution of their symptoms, adjust treatment, adapt therapeutic interventions and improve their quality of life. However, most consultations with the neurologist are bi-annual, and because of the long time lapse between two consultations, the practitioner often has only incomplete information on the evolution of symptoms.

To help fill these gaps, advances in digital health technologies, with the development of telemonitoring solutions, enable patients to be monitored remotely and provide a potentially more robust amount of information relating to the severity of the disease and its evolution over time. In this sense, remote monitoring in PD would enable the neurologist to readjust treatment at the right time and in the most appropriate way. This will be done by means of a weekly questionnaire (adapted from the clinical examination via the MDS-UPDRS scale) completed by the patient via a mobile application.

Remote monitoring of patients should improve their symptom management and quality of life, hence the interest in an intervention offering a remote monitoring service: DIGIPARK MONITOR.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson disease
  • Telemonitoring
  • Symptom management
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years ;
  • Parkinson's disease according to MDS diagnostic criteria ;
  • Classified as stage 1.5 to 3 according to the Hoehn and Yahr stages ;
  • Followed by a neurologist since at least one month;
  • Equipped with a smartphone or a computer or tablet with internet/cellular data access via the latter (or with the caregiver) ;
  • Resident on French territory affiliated to a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Person under guardianship, curatorship or safeguard of justice or any other administrative or judicial measure of deprivation of rights and freedom;
  • Patient suffering from dementia, mental disorders, cognitive disorders, or psychiatric pathology that could compromise the patient's and/or compliance with the study protocol;
  • Patient deemed non-autonomous by the investigator and without a caregiver;
  • Patient already included in another interventional research study, with the exception of NS-PARK's "PRECISE-PD" cohort.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Control arm

    conventional follow-up only, i.e. a consultation with the neurologist every 6 months

  • Experimental
    Telemonitoring arm

    remote monitoring using the DIGIPARK MONITOR application in addition to conventional monitoring.

    Device: DIGIPARK MONITOR

Interventions

  • DeviceDIGIPARK MONITOR

    remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.

06

What researchers measure

Primary outcomes

  1. Clinical effectiveness of telemonitoring on symptom progression in PD patients assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)

    total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration

    Time frame: 6 months

Secondary outcomes

  1. Evolution of PD patients' symptoms assessed by Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS)

    Total clinical examination score using the Movement Disorder Society- Unified Parkinson's Disease Rating scale (MDS-UPDRS). Score range from 0 to 200. A high score indicates clinical deterioration

    Time frame: 12 months

  2. Specific quality of Life assessed by Parkinson Disease Questionnaire (PD-Q39).

    score of Parkinson Disease Questionnaire (PD-Q39). Score range from 0 to 100. A high score indicates a deterioration

    Time frame: 12 months

  3. General quality of Life assessed by EuroQol-5 dimensions questionnaire

    Score of EuroQol-5 dimensions questionnaire. Score range from 0 to 100. A high score indicates a improvement

    Time frame: 12 months

  4. Organizational impact assessed by the number of consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations

    Percentage of patients who had a consultation that led to a paramedical and/or drug treatment rehabilitation between semi-annual consultations

    Time frame: 12 months

  5. Medico-economic impact

    Average total cost at 12 months in each group

    Time frame: 12 months

  6. Usability assessed by System Usability Scale.

    System Usability Scale. Score range from 1 to 100. A high score indicates a improvement

    Time frame: 12 months

  7. User's satisfaction assessed by a spécific questionnaire created for the study

    Satisfaction questionnaire created specifically for the study.Score range from 1 to 100. A high score indicates a improvement

    Time frame: 12 months

07

Study locations

10 sites
  • CHU Angers
    Angers, France
    • Frédérique ETCHARY-BOUYX · Contact
    • Frédérique ETCHARY-BOUYX, MD · Principal investigator
  • CH Flayriat
    Bourg-en-Bresse, France
    • Michel AZAR · Contact
    • Michel AZAR, MD · Principal investigator
  • CHU Caen
    Caen, France
    • Claire THIRIEZ · Contact
    • Claire THIRIEZ, MD · Principal investigator
  • Clinique du Plateau
    Clamart, France
    • Capucine MOUTHON-REIGNIER · Contact
    • Capucine MOUTHON-REIGNIER, MD · Principal investigator
  • CH Emile Roux
    Le Puy-en-Velay, France
    • Jérémie DASSA · Contact
    • Jérémie DASSA, MD · Principal investigator
  • Clinique Beau Soleil
    Montpellier, France
    • Valerie COHEN DE COCK · Contact
    • Valerie COHEN DE COCK, MD · Principal investigator
  • CHU Nice
    Nice, France
    • Caroline GIORDANA · Contact
    • Caroline GIORDANA, MD · Principal investigator
  • CH de Troyes
    Troyes, France
    • René DECOMBE · Contact
    • René DECOMBE, MD · Principal investigator
  • Hopital jean Bernard
    Valenciennes, France
    • Gilles RYCKEWAERT · Contact
    • Gilles RYCKEWAERT, MD · Principal investigator
  • Médipole Hôpital Mutuliste
    Villeurbanne, 69100, France
    • Adeline GIANINA, MD · Contact
    • Adeline GIANINA, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jan 2027, 30 months later.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 30 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 6, 2024
StartEst.
Jul 1, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Aug 1, 2027
Last update
May 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06401395
Lead sponsor
DIAMPARK
Collaborators
Weprom, Digital Medical Hub
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Jul 1, 2024 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
May 9, 2024

Study contacts

Magali BALAVOINE
Contact
m.balavoine@ilcgroupe.fr
+33241682940
Adeline GIANINA
principal investigator · Medipole Hopital Mutualiste

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion